Nevertheless, genotype-guided antiplatelet therapy is not yet standard care in patients with CAD, although genotype-guided de-escalation of P2Y12 inhibition has a class IIb guideline recommendation and can be considered for ACS patients deemed unsuitable for potent platelet inhibition, i.e., with a high bleeding risk.181. Here, P2RY12 is linked to coronary artery disorder.